Li J - Search Results

1

Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer.

Li J, Hu H, Qin G, Bai F, Wu X, Ke H, Zhang J, Xie Y, Wu Z, Fu Y, Zheng H, Gong L, Xie Z, Deng Y. Li J, et al. Clin Cancer Res. 2024 Jan 17;30(2):368-378. doi: 10.1158/1078-0432.CCR-23-2213. Clin Cancer Res. 2024. PMID: 37906636

2

[Choice of neoadjuvant therapy for rectal cancer: simple chemotherapy or synchronous chemoradiotherapy].

Li J, Deng Y, Wang J. Li J, et al. Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Jun 25;21(6):627-631. Zhonghua Wei Chang Wai Ke Za Zhi. 2018. PMID: 29968236 Chinese.

3

Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer.

Wu Z, Zhang J, Cai Y, Deng R, Yang L, Li J, Deng Y. Wu Z, et al. Among authors: li j. Medicine (Baltimore). 2018 Sep;97(38):e11435. doi: 10.1097/MD.0000000000011435. Medicine (Baltimore). 2018. PMID: 30235653 Free PMC article. Clinical Trial.

4

[Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].

Cai Y, Deng R, Hu H, Zhang J, Ling J, Wu Z, Yang L, Li J, Deng Y. Cai Y, et al. Among authors: li j. Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Sep 25;21(9):1045-1050. Zhonghua Wei Chang Wai Ke Za Zhi. 2018. PMID: 30269326 Chinese.

5

Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients.

Li J, Zhang J, Hu H, Cai Y, Ling J, Wu Z, Deng Y. Li J, et al. Cancer Manag Res. 2020 May 11;12:3301-3310. doi: 10.2147/CMAR.S243490. eCollection 2020. Cancer Manag Res. 2020. PMID: 32494194 Free PMC article.

6

Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component.

Li J, Yang L, Bai F, Cai Y, Zhang J, Wu Z, Fu Y, Deng Y. Li J, et al. Future Oncol. 2021 Apr;17(11):1351-1362. doi: 10.2217/fon-2020-1055. Epub 2020 Dec 17. Future Oncol. 2021. PMID: 33331169

7

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair.

Hu H, Wu Z, Wang C, Huang Y, Zhang J, Cai Y, Xie X, Li J, Shen C, Li W, Ling J, Xu X, Deng Y. Hu H, et al. Among authors: li j, li w. Front Oncol. 2020 Dec 4;10:579478. doi: 10.3389/fonc.2020.579478. eCollection 2020. Front Oncol. 2020. PMID: 33344234 Free PMC article.

8

LncRNA ENSG00000254615 Modulates Proliferation and 5-FU Resistance by Regulating p21 and Cyclin D1 in Colorectal Cancer.

Fu Y, Huang R, Li J, Xie X, Deng Y. Fu Y, et al. Among authors: li j. Cancer Invest. 2021 Oct;39(9):696-710. doi: 10.1080/07357907.2021.1923727. Epub 2021 Sep 1. Cancer Invest. 2021. PMID: 33938344

9

Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer.

Li J, Cai Y, Deng Y. Li J, et al. Curr Treat Options Oncol. 2021 Jun 7;22(7):55. doi: 10.1007/s11864-021-00852-1. Curr Treat Options Oncol. 2021. PMID: 34097129 Review.

10

Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies.

Zhang J, Xie X, Wu Z, Hu H, Cai Y, Li J, Ling J, Ding M, Li W, Deng Y. Zhang J, et al. Among authors: li j, li w. Clin Colorectal Cancer. 2021 Dec;20(4):e240-e248. doi: 10.1016/j.clcc.2021.06.004. Epub 2021 Jun 26. Clin Colorectal Cancer. 2021. PMID: 34334298

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

194,084 results

Search Page

Filters